In this clinical research study, we assessed 179 clinical cases of NSCLC previously tested for EGFR, KRAS, NRAS, and BRAF mutations using a novel multiplexed analytic approach that reduces wild-type signal and allows for detection of low mutation load approaching 1%, iPLEX® HS panel for the MassARRAY® System (Agena Bioscience, San Diego, CA). This evidence concerns the gene EGFR and non-small cell lung carcinoma.